Global Reperfusion Treatment Market
Global Reperfusion Treatment Market

Reperfusion Treatment Comprehensive Study by End users (Hospitals, Ambulatory surgery centers, Others), Treatment (Cyclosporin, Stem Cell Therapy, Therapeutic Hypothermia, Hydrogen Sulfide treatment, Others), Injury (Heart Injury, Kidney Injury, Intestine Injury, Others) Players and Region - Global Market Outlook to 2026

Reperfusion Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 233 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Reperfusion remedy is a scientific cure to fix blood flow, both via or around, blocked arteries, generally after a coronary heart assault (myocardial infarction (MI)). Reperfusion remedy consists of capsules and surgery. The tablets are thrombolytics and fibrinolytics used in a procedure known as thrombolysis. Reperfusion harm is tissue injury brought on by means of a lack of blood provide or oxygen, such as injury to the Genius after a stroke or the coronary heart after an episode of ischemia. Instead of everyday functioning, this kind of blood provide restoration motives infection and oxidative injury via inducing oxidative stress. Prompt restoration of blood grant to the myocardium can end result in a smaller infarct dimension and decrease mortality. This restoration, however, is recognised to reason coronary heart harm and, finally, reperfusion injury. Such injury has been linked to a prolong in reperfusion therapy.This growth is primarily driven by Rising prevalence of cardiovascular diseases.

Globally, a noticeable market trend is evident Technological improvements in treatment. Major Players, such as Corline Biomedical AB (Sweden), SBI Holdings Inc. (Japan), Pharming Group NV (Netherlands), Mallinckrodt Pharmaceuticals (United Kingdom), MIFCOR, Inc. (United States), CFM Pharma Holding B.V. (Sweden), Revive Therapeutics Ltd. (Canada), Faraday Pharmaceuticals (United States) and Radikal Therapeutics Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment, following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide. It destroys the hydrogen peroxide that is naturally generated as a response to acute ischemia reperfusion injury and also contributes to loss of muscle function and mass.

Market Drivers
  • Rising prevalence of cardiovascular diseases

Market Trend
  • Technological improvements in treatment

Restraints
  • Side effects associated with these treatment

Opportunities
Rising healthcare expenditure
Challenges
High cost associated with the reperfusion injury treatment

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Reperfusion Treatment Study Sheds Light on
— The Reperfusion Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Reperfusion Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Reperfusion Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Reperfusion Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Reperfusion Treatment Market?
Companies that are profiled in Global Reperfusion Treatment Market are Corline Biomedical AB (Sweden), SBI Holdings Inc. (Japan), Pharming Group NV (Netherlands), Mallinckrodt Pharmaceuticals (United Kingdom), MIFCOR, Inc. (United States), CFM Pharma Holding B.V. (Sweden), Revive Therapeutics Ltd. (Canada), Faraday Pharmaceuticals (United States) and Radikal Therapeutics Inc. (United States) etc.

3. What is Reperfusion Treatment Market?
Reperfusion remedy is a scientific cure to fix blood flow, both via or around, blocked arteries, generally after a coronary heart assault (myocardial infarction (MI)). Reperfusion remedy consists of capsules and surgery. The tablets are thrombolytics and fibrinolytics used in a procedure known as thrombolysis. Reperfusion harm is tissue injury brought on by means of a lack of blood provide or oxygen, such as injury to the Genius after a stroke or the coronary heart after an episode of ischemia. Instead of everyday functioning, this kind of blood provide restoration motives infection and oxidative injury via inducing oxidative stress. Prompt restoration of blood grant to the myocardium can end result in a smaller infarct dimension and decrease mortality. This restoration, however, is recognised to reason coronary heart harm and, finally, reperfusion injury. Such injury has been linked to a prolong in reperfusion therapy.
Report Objectives / Segmentation Covered
By End users
  • Hospitals
  • Ambulatory surgery centers
  • Others

By Treatment
  • Cyclosporin
  • Stem Cell Therapy
  • Therapeutic Hypothermia
  • Hydrogen Sulfide treatment
  • Others

By Injury
  • Heart Injury
  • Kidney Injury
  • Intestine Injury
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of cardiovascular diseases
    • 3.3. Market Challenges
      • 3.3.1. High cost associated with the reperfusion injury treatment
    • 3.4. Market Trends
      • 3.4.1. Technological improvements in treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Reperfusion Treatment, by End users, Treatment, Injury and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Reperfusion Treatment (Value)
      • 5.2.1. Global Reperfusion Treatment by: End users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Ambulatory surgery centers
        • 5.2.1.3. Others
      • 5.2.2. Global Reperfusion Treatment by: Treatment (Value)
        • 5.2.2.1. Cyclosporin
        • 5.2.2.2. Stem Cell Therapy
        • 5.2.2.3. Therapeutic Hypothermia
        • 5.2.2.4. Hydrogen Sulfide treatment
        • 5.2.2.5. Others
      • 5.2.3. Global Reperfusion Treatment by: Injury (Value)
        • 5.2.3.1. Heart Injury
        • 5.2.3.2. Kidney Injury
        • 5.2.3.3. Intestine Injury
        • 5.2.3.4. Others
      • 5.2.4. Global Reperfusion Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Reperfusion Treatment (Price)
  • 6. Reperfusion Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Corline Biomedical AB (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. SBI Holdings Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pharming Group NV (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MIFCOR, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CFM Pharma Holding B.V. (Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Revive Therapeutics Ltd. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Faraday Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Radikal Therapeutics Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Reperfusion Treatment Sale, by End users, Treatment, Injury and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Reperfusion Treatment (Value)
      • 7.2.1. Global Reperfusion Treatment by: End users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Ambulatory surgery centers
        • 7.2.1.3. Others
      • 7.2.2. Global Reperfusion Treatment by: Treatment (Value)
        • 7.2.2.1. Cyclosporin
        • 7.2.2.2. Stem Cell Therapy
        • 7.2.2.3. Therapeutic Hypothermia
        • 7.2.2.4. Hydrogen Sulfide treatment
        • 7.2.2.5. Others
      • 7.2.3. Global Reperfusion Treatment by: Injury (Value)
        • 7.2.3.1. Heart Injury
        • 7.2.3.2. Kidney Injury
        • 7.2.3.3. Intestine Injury
        • 7.2.3.4. Others
      • 7.2.4. Global Reperfusion Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Reperfusion Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Reperfusion Treatment: by End users(USD Million)
  • Table 2. Reperfusion Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 3. Reperfusion Treatment Ambulatory surgery centers , by Region USD Million (2015-2020)
  • Table 4. Reperfusion Treatment Others , by Region USD Million (2015-2020)
  • Table 5. Reperfusion Treatment: by Treatment(USD Million)
  • Table 6. Reperfusion Treatment Cyclosporin , by Region USD Million (2015-2020)
  • Table 7. Reperfusion Treatment Stem Cell Therapy , by Region USD Million (2015-2020)
  • Table 8. Reperfusion Treatment Therapeutic Hypothermia , by Region USD Million (2015-2020)
  • Table 9. Reperfusion Treatment Hydrogen Sulfide treatment , by Region USD Million (2015-2020)
  • Table 10. Reperfusion Treatment Others , by Region USD Million (2015-2020)
  • Table 11. Reperfusion Treatment: by Injury(USD Million)
  • Table 12. Reperfusion Treatment Heart Injury , by Region USD Million (2015-2020)
  • Table 13. Reperfusion Treatment Kidney Injury , by Region USD Million (2015-2020)
  • Table 14. Reperfusion Treatment Intestine Injury , by Region USD Million (2015-2020)
  • Table 15. Reperfusion Treatment Others , by Region USD Million (2015-2020)
  • Table 16. South America Reperfusion Treatment, by Country USD Million (2015-2020)
  • Table 17. South America Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 18. South America Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 19. South America Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 20. Brazil Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 21. Brazil Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 22. Brazil Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 23. Argentina Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 24. Argentina Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 25. Argentina Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 26. Rest of South America Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 27. Rest of South America Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Rest of South America Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 29. Asia Pacific Reperfusion Treatment, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 31. Asia Pacific Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 32. Asia Pacific Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 33. China Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 34. China Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 35. China Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 36. Japan Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 37. Japan Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 38. Japan Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 39. India Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 40. India Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 41. India Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 42. South Korea Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 43. South Korea Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 44. South Korea Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 45. Taiwan Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 46. Taiwan Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 47. Taiwan Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 48. Australia Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 49. Australia Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 50. Australia Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 54. Europe Reperfusion Treatment, by Country USD Million (2015-2020)
  • Table 55. Europe Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 56. Europe Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 57. Europe Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 58. Germany Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 59. Germany Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 60. Germany Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 61. France Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 62. France Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 63. France Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 64. Italy Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 65. Italy Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 66. Italy Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 67. United Kingdom Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 68. United Kingdom Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 69. United Kingdom Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 70. Netherlands Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 71. Netherlands Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 72. Netherlands Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 73. Rest of Europe Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 74. Rest of Europe Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 75. Rest of Europe Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 76. MEA Reperfusion Treatment, by Country USD Million (2015-2020)
  • Table 77. MEA Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 78. MEA Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 79. MEA Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 80. Middle East Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 81. Middle East Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 82. Middle East Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 83. Africa Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 84. Africa Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 85. Africa Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 86. North America Reperfusion Treatment, by Country USD Million (2015-2020)
  • Table 87. North America Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 88. North America Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 89. North America Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 90. United States Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 91. United States Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 92. United States Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 93. Canada Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 94. Canada Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 95. Canada Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 96. Mexico Reperfusion Treatment, by End users USD Million (2015-2020)
  • Table 97. Mexico Reperfusion Treatment, by Treatment USD Million (2015-2020)
  • Table 98. Mexico Reperfusion Treatment, by Injury USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Reperfusion Treatment: by End users(USD Million)
  • Table 109. Reperfusion Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 110. Reperfusion Treatment Ambulatory surgery centers , by Region USD Million (2021-2026)
  • Table 111. Reperfusion Treatment Others , by Region USD Million (2021-2026)
  • Table 112. Reperfusion Treatment: by Treatment(USD Million)
  • Table 113. Reperfusion Treatment Cyclosporin , by Region USD Million (2021-2026)
  • Table 114. Reperfusion Treatment Stem Cell Therapy , by Region USD Million (2021-2026)
  • Table 115. Reperfusion Treatment Therapeutic Hypothermia , by Region USD Million (2021-2026)
  • Table 116. Reperfusion Treatment Hydrogen Sulfide treatment , by Region USD Million (2021-2026)
  • Table 117. Reperfusion Treatment Others , by Region USD Million (2021-2026)
  • Table 118. Reperfusion Treatment: by Injury(USD Million)
  • Table 119. Reperfusion Treatment Heart Injury , by Region USD Million (2021-2026)
  • Table 120. Reperfusion Treatment Kidney Injury , by Region USD Million (2021-2026)
  • Table 121. Reperfusion Treatment Intestine Injury , by Region USD Million (2021-2026)
  • Table 122. Reperfusion Treatment Others , by Region USD Million (2021-2026)
  • Table 123. South America Reperfusion Treatment, by Country USD Million (2021-2026)
  • Table 124. South America Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 125. South America Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 126. South America Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 127. Brazil Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 128. Brazil Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 129. Brazil Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 130. Argentina Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 131. Argentina Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 132. Argentina Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 133. Rest of South America Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 134. Rest of South America Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 135. Rest of South America Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 136. Asia Pacific Reperfusion Treatment, by Country USD Million (2021-2026)
  • Table 137. Asia Pacific Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 138. Asia Pacific Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 139. Asia Pacific Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 140. China Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 141. China Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 142. China Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 143. Japan Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 144. Japan Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 145. Japan Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 146. India Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 147. India Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 148. India Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 149. South Korea Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 150. South Korea Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 151. South Korea Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 152. Taiwan Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 153. Taiwan Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 154. Taiwan Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 155. Australia Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 156. Australia Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 157. Australia Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 161. Europe Reperfusion Treatment, by Country USD Million (2021-2026)
  • Table 162. Europe Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 163. Europe Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 164. Europe Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 165. Germany Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 166. Germany Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 167. Germany Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 168. France Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 169. France Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 170. France Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 171. Italy Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 172. Italy Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 173. Italy Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 174. United Kingdom Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 175. United Kingdom Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 176. United Kingdom Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 177. Netherlands Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 178. Netherlands Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 179. Netherlands Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 180. Rest of Europe Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 181. Rest of Europe Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 182. Rest of Europe Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 183. MEA Reperfusion Treatment, by Country USD Million (2021-2026)
  • Table 184. MEA Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 185. MEA Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 186. MEA Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 187. Middle East Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 188. Middle East Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 189. Middle East Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 190. Africa Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 191. Africa Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 192. Africa Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 193. North America Reperfusion Treatment, by Country USD Million (2021-2026)
  • Table 194. North America Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 195. North America Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 196. North America Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 197. United States Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 198. United States Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 199. United States Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 200. Canada Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 201. Canada Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 202. Canada Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 203. Mexico Reperfusion Treatment, by End users USD Million (2021-2026)
  • Table 204. Mexico Reperfusion Treatment, by Treatment USD Million (2021-2026)
  • Table 205. Mexico Reperfusion Treatment, by Injury USD Million (2021-2026)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Reperfusion Treatment: by End users USD Million (2015-2020)
  • Figure 5. Global Reperfusion Treatment: by Treatment USD Million (2015-2020)
  • Figure 6. Global Reperfusion Treatment: by Injury USD Million (2015-2020)
  • Figure 7. South America Reperfusion Treatment Share (%), by Country
  • Figure 8. Asia Pacific Reperfusion Treatment Share (%), by Country
  • Figure 9. Europe Reperfusion Treatment Share (%), by Country
  • Figure 10. MEA Reperfusion Treatment Share (%), by Country
  • Figure 11. North America Reperfusion Treatment Share (%), by Country
  • Figure 12. Global Reperfusion Treatment share by Players 2020 (%)
  • Figure 13. Global Reperfusion Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Reperfusion Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Corline Biomedical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 17. Corline Biomedical AB (Sweden) Revenue: by Geography 2020
  • Figure 18. SBI Holdings Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 19. SBI Holdings Inc. (Japan) Revenue: by Geography 2020
  • Figure 20. Pharming Group NV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Pharming Group NV (Netherlands) Revenue: by Geography 2020
  • Figure 22. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 24. MIFCOR, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. MIFCOR, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. CFM Pharma Holding B.V. (Sweden) Revenue, Net Income and Gross profit
  • Figure 27. CFM Pharma Holding B.V. (Sweden) Revenue: by Geography 2020
  • Figure 28. Revive Therapeutics Ltd. (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Revive Therapeutics Ltd. (Canada) Revenue: by Geography 2020
  • Figure 30. Faraday Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Faraday Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 32. Radikal Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Radikal Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Global Reperfusion Treatment: by End users USD Million (2021-2026)
  • Figure 35. Global Reperfusion Treatment: by Treatment USD Million (2021-2026)
  • Figure 36. Global Reperfusion Treatment: by Injury USD Million (2021-2026)
  • Figure 37. South America Reperfusion Treatment Share (%), by Country
  • Figure 38. Asia Pacific Reperfusion Treatment Share (%), by Country
  • Figure 39. Europe Reperfusion Treatment Share (%), by Country
  • Figure 40. MEA Reperfusion Treatment Share (%), by Country
  • Figure 41. North America Reperfusion Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Corline Biomedical AB (Sweden)
  • SBI Holdings Inc. (Japan)
  • Pharming Group NV (Netherlands)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • MIFCOR, Inc. (United States)
  • CFM Pharma Holding B.V. (Sweden)
  • Revive Therapeutics Ltd. (Canada)
  • Faraday Pharmaceuticals (United States)
  • Radikal Therapeutics Inc. (United States)
Additional players considered in the study are as follows:
Amyndas Pharmaceuticals (United States) , Perfusion.com, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation